This result is consistent with the view of Raja et al.85 It turned out that the potential combination of anti-HER2 scFv–HSA fusion antibody-based ADCs with an HSP90 inhibitor may provide a novel strategy to improve the therapeutic efficacy of cancer. This evidence concerns the gene ERBB2 and cancer.